tiprankstipranks
Trending News
More News >

Cyclopharm Reports Revenue Growth Amidst Strategic Investments

Story Highlights
Cyclopharm Reports Revenue Growth Amidst Strategic Investments

Confident Investing Starts Here:

Cyclopharm Limited ( (AU:CYC) ) just unveiled an announcement.

Cyclopharm Limited reported a 4.7% increase in group sales revenue to $27.57 million for the financial year ending December 2024. Despite the revenue growth, the company faced a net loss of $13.2 million, attributed to increased investments in developing new clinical applications for its Technegas™ product, which is expected to provide significant long-term growth opportunities.

More about Cyclopharm Limited

Cyclopharm Limited operates in the healthcare industry, focusing on the development and distribution of medical technologies. The company is known for its Technegas™ product, which is used in nuclear medicine imaging and is exploring new clinical applications for long-term growth.

YTD Price Performance: 25.55%

Average Trading Volume: 110,032

Technical Sentiment Consensus Rating: Strong Sell

Current Market Cap: A$221.2M

Learn more about CYC stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1